-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascendiant Capital Maintains Buy on GRI Bio, Lowers Price Target to $40

Benzinga·03/11/2026 12:44:45
Listen to the news
Ascendiant Capital analyst Edward Woo maintains GRI Bio (NASDAQ:GRI) with a Buy and lowers the price target from $1008 to $40.